Last updated: 2026-10-19 20:48:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
UroGen Pharma Ltd. (URGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $34.14, with a market capitalization of $1.69B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.37 to $50.81. This page covers its latest market performance, valuation, price trends and company information.
$1.69B | |
$34.75 | |
$69.57 | |
$3.42 | |
$34.56 | |
946.25K | |
887.73K | |
-- | |
$50.81 | |
$16.36 | |
-- | |
-- |
UroGen Pharma Ltd. (URGN) is trading at $34.14 in after-hours trading as of 2026-10-19 20:36:00, down 1.23% ($0.43) from the regular-session close of $34.56.
After-hours trading shows how investors are pricing URGN after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, UroGen Pharma Ltd. (URGN) moved from $36.98 to $34.14, representing a decline of 7.67% ($2.84).
The stock traded between $33.48 and $40.05 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.43 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 51.6%
URGN is currently trading at $34.14, placing it 51.6% of the way from its 52-week low of $16.37 to its 52-week high of $50.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 291 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of UroGen Pharma Ltd. (URGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.